Labetuzumab

Labetuzumab is a humanised anti-carcinoembryonic antigen (CEA) monoclonal antibody that inhibits tumour growth and sensitises human medullary thyroid cancer xenografts to Dacarbazine chemotherapy[1].

Product Specifications

CAS Number

[219649-07-7]

Product Name Alternative

HMN14

UNSPSC

12352203

Target

Transmembrane Glycoprotein

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/labetuzumab.html

Purity

99.59

Solubility

10 mM in DMSO

Smiles

[Labetuzumab]

Molecular Weight

(145.48 kDa)

References & Citations

[1]Stein R, et al. A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, inhibits tumor growth and sensitizes human medullary thyroid cancer xenografts to dacarbazine chemotherapy. Mol Cancer Ther. 2004 Dec;3 (12) :1559-64.